Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HERTHENA-PanTumor01
NCT06172478Phase 2Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Feb 2024
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies
- Countries
- 16
01
Overview
Phase 2, open-label, single-arm trial of patritumab deruxtecan in solid tumor, melanoma, squamous cell carcinoma of the head and neck (HNSCC) and 10 more, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Objective Response Rate and Proportion of Participants Achieving a >=50% Decrease in PSA. Started Feb 2024; status: recruiting.
02
Drugs
patritumab deruxtecan
03
Conditions
solid tumormelanomasquamous cell carcinoma of the head and neck (HNSCC)gastric cancer (GC)ovarian cancer
Beyond the preview
Go deeper on NCT06172478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06172478.